ALXO News and Press, ALX Oncology Holdings Inc. From 10/07/21

Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugates Expands ALX Oncology’s pipeline of drug candidates based on expertise in protein engineeri...

Zymeworks (NYSE:ZYME) and ALX Oncology Holdings (NASDAQ:ALXO) announce the first patient has been dosed in the early-stage trial of zanidatamab in certain patients with breast cancer. The trial is designed to evaluate the safety and efficacy of zanidatamab in combination with evorpacept ...

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the fi...

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that four abstracts...

BURLINGAME, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the initiation of a Phase 1/2 investigator-...

Lightstone Ventures Raises $375 Million Fund Fund III will continue firm's work partnering with entrepreneurs developing breakthrough therapies and medical technologies Christina Isacson, Ph.D., joins as Partner and Young Kwon, Ph.D., as Operating Partner PR Newswire ...

With recent buyouts of Trillium Therapeutics and Forty Seven Inc. in the CD47 space, it's my belief that should ALX Oncology deliver on data it could be next. ALX's CD47 drug ALX148 (Evorpacept) has shown great early clinical evidence in a few studies, and the drug already has seen in...

Investing in biotech companies is hard. Shareholders are often subject to wild price swings based on results that may not translate to future studies. But when a drug succeeds, the gains can be extraordinary. That's why it pays to be diversified and make sure you are comfortable with the le...

Gainers: Trillium Therapeutics (NASDAQ:TRIL) +187%, Vivos Therapeutics (NASDAQ:VVOS) +57%, Xeris Pharmaceuticals (NASDAQ:XERS) +19%, ALX Oncology (NASDAQ:ALXO) +24%, Candel Therapeutics (NASDAQ:CADL) +20%. Losers: Flora Growth (NASDAQ:FLGC) -10%,&#...

Trillium Therapeutics (NASDAQ:TRIL) +191% after acquisition by Pfizer for $2.3B Vivos Therapeutics (NASDAQ:VVOS) +61% on FDA 510k clearance for sleep apnea treatment device Xeris Pharmaceuticals (NASDAQ:XERS) +48% announces approval of supplemental new drug Application (sN...